Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Feb 6, 2024
Deals

MorphoSys’ long run ends with €2.7B Novartis takeout

Shift to product-focused company positioned German biotech for deal giving former Constellation assets to Swiss pharma
BioCentury | Nov 20, 2023
Regulation

Nov. 20 Quick Takes: Mixed myelofibrosis results from MorphoSys’ pelabresib

Plus: Regulatory delay for BMS, 2seventy’s Abecma, and updates from AstraZeneca and Ibiome
BioCentury | Mar 11, 2023
Emerging Company Profile

Opna Bio: targeting FMRP to treat cancer

Company’s other five small molecules come from CEO Gideon Bollag’s former company, Plexxikon
BioCentury | Mar 4, 2023
Regulation

March 3 Quick Takes: Praxis aims to start Phase III essential tremor study despite Phase II miss 

Plus: Incyte stopping Jakafi myelofibrosis combo study and updates from Exelixis, Sangamo, BMS, Veru
BioCentury | Jan 6, 2023
Product Development

Kornowski shifts gears at Boston Pharma, sets NASH program as top priority

Ex-Roche exec refines focus, decides what to keep and commercialize vs. what to partner out
BioCentury | Apr 1, 2022
Distillery Therapeutics

Expandable pancreatic progenitor cells for diabetes

BioCentury | Dec 3, 2021
Distillery Therapeutics

Computational identification of cancer compounds for PAH

BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

BioCentury’s analysis of ASCO 2019 abstracts shows bispecifics outpacing CAR Ts in solid tumors
Items per page:
1 - 10 of 55
Help Center
Username
Request a Demo
Request Training
Ask a Question